Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Phase II study of Theratope for metastatic breast cancer completes enrollment

July 29, 2004

Survival benefits of Canvaxin in metastatic melanoma

July 29, 2004

Combination regimens in the treatment of CTCL

July 29, 2004

Antisoma gains rights to BC1-IL12

July 28, 2004

New phase II biomarker trial for SGN-15

July 27, 2004

First phase III study of GVAX prostate cancer vaccine commences enrollment

July 21, 2004

Therapeutic benefits of recombinant PSA vaccines in advanced prostate cancer

July 13, 2004

European orphan medicinal product status for Mepat in osteosarcoma

July 12, 2004

Dosing commences in phase III trial of TransMID for glioblastoma multiforme

July 8, 2004

AltaRex signs distribution agreement with Dompe

July 8, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...